药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
Ranibizumab
Lanthanum carbonate
The absorption of Pitavastatin can be decreased when combined with Lanthanum carbonate.
Ranibizumab
Mometasone furoate
The metabolism of Pitavastatin can be decreased when combined with Mometasone furoate.
Ranibizumab
Fluticasone
The metabolism of Pitavastatin can be decreased when combined with Fluticasone.
Ranibizumab
Trametinib
The metabolism of Pitavastatin can be decreased when combined with Trametinib.
Ranibizumab
Fluticasone furoate
The metabolism of Pitavastatin can be decreased when combined with Fluticasone furoate.
Ranibizumab
Sulfaphenazole
The metabolism of Pitavastatin can be decreased when combined with Sulfaphenazole.
Ranibizumab
Medical Cannabis
The metabolism of Pitavastatin can be decreased when combined with Medical Cannabis.
Ranibizumab
Iproniazid
The metabolism of Pitavastatin can be decreased when combined with Iproniazid.
Ranibizumab
Fenofibric acid
The risk or severity of myopathy and rhabdomyolysis can be increased when Fenofibric acid is combined with Pitavastatin.
Ranibizumab
Clofibride
The risk or severity of myopathy and rhabdomyolysis can be increased when Clofibride is combined with Pitavastatin.
Ranibizumab
Aluminium clofibrate
The risk or severity of myopathy and rhabdomyolysis can be increased when Aluminium clofibrate is combined with Pitavastatin.
Ranibizumab
Ronifibrate
The risk or severity of myopathy and rhabdomyolysis can be increased when Ronifibrate is combined with Pitavastatin.
Ranibizumab
Simfibrate
The risk or severity of myopathy and rhabdomyolysis can be increased when Simfibrate is combined with Pitavastatin.
Ranibizumab
Etofibrate
The risk or severity of myopathy and rhabdomyolysis can be increased when Etofibrate is combined with Pitavastatin.
Ranibizumab
Tioclomarol
The risk or severity of bleeding can be increased when Pitavastatin is combined with Tioclomarol.
Ranibizumab
Diphenadione
The risk or severity of bleeding can be increased when Pitavastatin is combined with Diphenadione.
Ranibizumab
Clorindione
The risk or severity of bleeding can be increased when Pitavastatin is combined with Clorindione.
Ranibizumab
Ethyl biscoumacetate
The risk or severity of bleeding can be increased when Pitavastatin is combined with Ethyl biscoumacetate.
Ranibizumab
Coumarin
The risk or severity of bleeding can be increased when Pitavastatin is combined with Coumarin.
Ranibizumab
4-hydroxycoumarin
The risk or severity of bleeding can be increased when Pitavastatin is combined with 4-hydroxycoumarin.